Protalix BioTherapeutics Inc.
Protalix BioTherapeutics Inc.
06/25/2026 | Press release | Distributed by Public on 06/25/2026 14:30
Proxy Results (Form 8-K)
|
Item 5.07 |
Submission of Matters to a Vote of Security Holders |
Protalix Biotherapeutics, Inc. (the "Company") convened its 2026 Annual Meeting of Stockholders (the "Meeting") at 8:00 A.M. EDT on June 25, 2026 at the offices of LifeSci Advisors, Azrieli Center Round Tower, Derech Menachem Begin 132, 11th Floor, Tel Aviv 6701203, Israel. The Company's stockholders: (1) elected the eight persons nominated by the Company's Board of Directors to serve as directors of the Company; (2) approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers; (3) approved an Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan (the "Plan"), to increase the number of shares of common stock available under the Plan from 17,475,171 shares to 20,975,171 shares and to amend certain other terms of the Plan; and and (4) ratified the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a Member of PricewaterhouseCoopers International Limited, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Set forth below, with respect to each proposal adopted at the Meeting, are the number of votes cast for or against or withheld, as applicable, the number of abstentions and the number of broker non-votes.
(1)Election of Directors
|
|
|
Broker |
|
|
Eliot Richard Forster, Ph.D. |
32,871,013 |
2,379,140 |
10,705,177 |
|
Dror Bashan |
32,023,297 |
3,085,555 |
10,705,177 |
|
Amos Bar Shalev |
28,788,428 |
6,461,724 |
10,705,177 |
|
Shmuel "Muli" Ben Zvi, Ph.D. |
31,573,749 |
3,676,403 |
10,705,177 |
|
Pol F. Boudes, M.D. |
32,649,206 |
2,600,947 |
10,705,177 |
|
Christian Elze |
32,639,041 |
2,611,111 |
10,705,177 |
|
Gwen A. Melincoff |
32,784,702 |
2,465,451 |
10,705,177 |
|
Aharon Schwartz, Ph.D. |
30,334,262 |
4,915,890 |
10,705,177 |
(2)Approval, on a non-binding, advisory basis, the compensation of the Company's named executive officers
|
|
|
|
Broker |
|
28,368,614 |
6,683,937 |
197,602 |
10,705,177 |
(3)Approval of the Plan to increase the number of shares of common stock available under the Plan from 17,475,171 shares to 20,975,171 shares and to amend certain other terms of the Plan
|
|
|
|
Broker |
|
28,161,656 |
6,974,902 |
113,594 |
10,705,177 |
(4)Ratification of the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a Member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2026. A majority of the shares present in person or represented by proxy at the meeting and entitled to vote voted affirmatively in favor of the proposal. The number of votes cast with respect to this matter was as follows:
|
For |
Against |
Abstain |
|
42,958,243 |
2,001,734 |
995,352 |
Protalix BioTherapeutics Inc. published this content on June 25, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 25, 2026 at 20:30 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]